New Zealand medicinal cannabis company Helius appoints new board member.
Joanna Perry MNZM has been appointed to the board of New Zealand licenced medicinal cannabis company Helius Therapeutics.
The chartered accountant fellow joins as an independent director and will chair the board’s Audit Finance Committee.
Perry’s appointment comes as the 100% New Zealand-owned private company prepares to enter both domestic and international markets.
“Joanna’s significant governance experience, combined with her well-known inquisitive probing, will be a real asset,” Helius chief executive Carmen Doran said.
Perry holds other senior independent directorships. As with many previous governance roles, she often leads responsibility for audit and risk. She has held many regulatory, advisory, standards and reporting-related roles, and was a long-time member of the former Crown entity, Securities Commission of New Zealand.
The Cambridge University graduate was awarded a Member New Zealand Order of Merit for Services to Accounting.
Perry said: “I’m delighted to add my governance and financial experience to the vast pharmaceutical and cannabinoid medicine experience of the Helius team.”
Perry has previously worked with the company’s cornerstone shareholder and chair, NBR Lister Guy Haddleton and was looking forward to again, saying: “I respect Guy’s steadfast commitment to business innovation globally. I also admire his personal passion to deliver safe and effective medicinal cannabis here in New Zealand to improve patients’ quality of life. He has built the team to get the job done.”
This is supplied content and not commissioned or paid for by NBR.
